| Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses T Kumai, S Lee, HI Cho, H Sultan, H Kobayashi, Y Harabuchi, E Celis Cancer immunology research 5 (1), 72-83, 2017 | 68 | 2017 |
| Poly-ICLC, a multi-functional immune modulator for treating cancer H Sultan, AM Salazar, E Celis Seminars in immunology 49, 101414, 2020 | 47 | 2020 |
| The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice H Sultan, T Kumai, T Nagato, J Wu, AM Salazar, E Celis Cancer Immunology, Immunotherapy 68, 455-466, 2019 | 46 | 2019 |
| Designing therapeutic cancer vaccines by mimicking viral infections H Sultan, VI Fesenkova, D Addis, AE Fan, T Kumai, J Wu, AM Salazar, ... Cancer Immunology, Immunotherapy 66, 203-213, 2017 | 46 | 2017 |
| Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration H Sultan, J Wu, VI Fesenkova, AE Fan, D Addis, AM Salazar, E Celis Journal for immunotherapy of cancer 8 (2), 2020 | 43 | 2020 |
| Role of dendritic cell-mediated immune response in oral homeostasis: A new mechanism of osteonecrosis of the jaw R Elsayed, Z Kurago, CW Cutler, R Arce, J Gerber, E Celis, H Sultan, ... FASEB journal: official publication of the Federation of American Societies …, 2020 | 34 | 2020 |
| Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice H Sultan, J Wu, T Kumai, AM Salazar, E Celis Cancer Immunology, Immunotherapy 67, 1091-1103, 2018 | 24 | 2018 |
| Effective antitumor peptide vaccines can induce severe autoimmune pathology H Sultan, J Trillo-Tinoco, P Rodriguez, E Celis Oncotarget 8 (41), 70317, 2017 | 16 | 2017 |
| Sustained persistence of IL2 signaling enhances the antitumor effect of peptide vaccines through T-cell expansion and preventing PD-1 inhibition H Sultan, T Kumai, VI Fesenkova, AE Fan, J Wu, HI Cho, H Kobayashi, ... Cancer immunology research 6 (5), 617-627, 2018 | 14 | 2018 |
| 31st annual meeting and associated programs of the society for immunotherapy of cancer (Sitc 2016): Part two: National harbor, md, USA. 9-13 November 2016 C Ager, M Reilley, C Nicholas, T Bartkowiak, A Jaiswal, M Curran, ... Journal for ImmunoTherapy of Cancer 4, 107-221, 2016 | 12 | 2016 |
| Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses. Cancer Immunol. Res. 2017; 5: 72–83. doi: 10.1158/2326-6066 T Kumai, S Lee, HI Cho, H Sultan, H Kobayashi, Y Harabuchi, E Celis CIR-16-0194.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 8 | |
| Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses. Cancer Immunol Res. 2017; 5 (1): 72–83. doi: 10.1158/2326-6066 T Kumai, S Lee, HI Cho, H Sultan, H Kobayashi, Y Harabuchi, E Celis CIR-16-0194, 0 | 5 | |
| 578 CD8-targeted IL-2 drives potent anti-tumor efficacy and promotes action of tumor specific vaccines H Sultan, K Moynihan, Y Song, S Ameh, T Schumacher, YA Yeung, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), A607-A607, 2021 | 4 | 2021 |
| The effect of α1-antitrypsin deficiency combined with increased bacterial loads on chronic obstructive pulmonary disease pharmacotherapy: a prospective, parallel, controlled … MG Hennawy, NM Elhosseiny, H Sultan, W Abdelfattah, Y Akl, NA Sabry, ... Journal of Advanced Research 7 (6), 1019-1028, 2016 | 3 | 2016 |
| CD4 T Cells in Antitumor Immunity V Fesenkova, H Sultan, E Celis | 3 | 2016 |
| 1083 AB821 is a CD8+ T cell selective IL-21 with enhanced bioavailability that mediates potent anti-tumor activity, cytotoxicity, and expansion of memory CD8+ T cells R Greer, H Nguyen, P Mesko, R Lan, WW Prior, H Sultan, M Sukthankar, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 2 | 2022 |
| 1092 The CD8+ T cell selectivity of AB248 is essential for optimal anti-tumor activity and safety in nonclinical models K Moynihan, D Pappas, H Sultan, T Park, M Kumar, R Lan, I Ni, J Chen, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 2 | 2022 |
| IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity KD Moynihan, MP Kumar, H Sultan, DC Pappas, T Park, SM Chin, ... Cancer Discovery, OF1-OF20, 2024 | | 2024 |
| 1006 High doses of MHC-II neoantigens in peptide cancer vaccines induce tumor-specific inhibitory cytolytic CD4+ T cells H Sultan, Y Takeuchi, J Ward, M Firulyova, TT Liu, N Sharma, Y Song, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Abstract PO011: Systemic administration of Poly-ICLC promotes T cell tumor infiltration generating antitumor responses H Sultan, J Wu, V Fesenkova, A Fan, D Addis, A Salazar, E Celis Cancer Immunology Research 9 (2_Supplement), PO011-PO011, 2021 | | 2021 |
Juan WuVerified email at augusta.edu
